Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Dysfunctional uterine bleeding (DUB), characterized by way of irregular menstrual bleeding in the absence of organic pathology, affects a wide variety of girls globally, with varying occurrence rates prompted by way of factors inclusive of age, hormonal fluctuations, and underlying clinical situations. Technological advancements in diagnostic gear, which include ultrasound, endometrial biopsy, and hormonal assays, have improved the accuracy and performance of diagnosing DUB, leading to early detection and well-timed treatment initiation, thereby influencing market increase. The DUB market is influenced by the aid of a number of remedy alternatives, along with hormonal medicines, which include oral contraceptives, progestins, and gonadotropin-releasing hormone (GnRH) agonists, in addition to non-hormonal treatment options like tranexamic acid, surgical interventions, and endometrial ablation tactics geared toward managing peculiar uterine bleeding.
Public consciousness campaigns, educational initiatives by using healthcare agencies, and accelerated media coverage of DUB symptoms, chance factors, and remedy alternatives play a pivotal function in driving early popularity, diagnosis, and remedy-searching for behavior amongst affected women. Ongoing study efforts geared toward understanding the underlying mechanisms of DUB, figuring out novel treatment objectives, and developing modern treatments make contributions to the evolution of the market and medical management of the circumstance. The extent of medical insurance, repayment guidelines, and out-of-pocket fees affect women's entry to DUB treatments and healthcare offerings, thereby shaping market dynamics and remedy usage styles. The DUB treatment market is characterized by competitive dynamics, with a couple of pharmaceutical businesses, medical tool producers, and healthcare companies vying for market percentage through product innovation, advertising strategies, and pricing.
Socioeconomic factors, such as earnings ranges, monetary balance, and healthcare spending, affect the affordability of DUB remedies girls' capacity to access specialized care and contribute to market variations throughout exclusive socioeconomic strata. Advances in drug formulations, transport structures, minimally invasive surgical strategies, and virtual health solutions have the potential to improve treatment outcomes, patient pleasure, and market penetration of DUB healing procedures. International alternate agreements, tariffs, and regulatory harmonization efforts impact the provision, pricing, and market entry to DUB treatments on a global scale, influencing market dynamics and competition amongst market gamers. Changing client options, tendencies towards non-hormonal remedies, improved emphasis on holistic procedures for ladies' health, and patient preferences for specific treatment modalities impact market demand for DUB remedies and affect product improvement techniques.
Dysfunctional Uterine Bleeding Market Highlights:
Dysfunctional Uterine Bleeding Market Overview
The dysfunctional uterine bleeding market is expected to to reach USD 5,389.76 Million by 2030 at CAGR of 7.20% during the forecast 2020-2030. Dysfunctional uterine bleeding, also known as abnormal uterine bleeding, is irregular bleeding occurring in the absence of any recognizable pelvic pathology. Pregnancy is a common cause of abnormal uterine bleeding. The main causes of uterine bleeding can be fibroids in the uterus, infection of the cervix, and cancer of the uterus in some cases. Medications causing dysfunctional uterine bleeding are birth control pills, hormonal agents, and Coumadin.
Rising prevalence of uterine disorders such as uterine cancer, polycystic ovary syndrome, endometriosis, and uterine polyps drive the dysfunctional uterine bleeding market growth. Furthermore, rising prevalence of uterine cancer, and demand for diagnosis and treatment measures also influence the dysfunctional uterine bleeding market growth. According to the Cancer Research, in 2014, 9324 new cases of uterine cancer were diagnosed in U.K and the number is expected to increase in the near future.
According to the World Cancer Research Fund International, endometrial cancer is the sixth most common cancer in women worldwide, with 320,000 new cases diagnosed in 2012. It also stated that about 53% of endometrial cancer cases occurred in the developed countries.FIGURE 1: Global Dysfunctional Uterine Bleeding Market by Region, 2016 (%)
 
U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
 Key Players in the Dysfunctional Uterine Bleeding Market
Some of the key players in dysfunctional uterine bleeding market are B. Braun Melsungen AG (Germany), Hologic Inc. (U.S.), Karl Storz Gmbh & Co. KG (Germany), Medgyn Products, Inc., Olympus (Japan), Richard Wolf GmbH (Germany), Stryker (U.S.), Xion Medical GmbH (Germany), Cadila Pharmaceuticals Ltd. (India), Torrent Phamraceuticals (India).
Segments   Â
The dysfunctional uterine bleeding market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of type, dysfunctional uterine bleeding market is segmented into ovulatory, and anovulatory.
On the basis of diagnosis, the dysfunctional uterine bleeding market is segmented into hysteroscopy, ultrasonography, dilation and curettage, endometrial biopsy, and others.
On the basis of treatment, the dysfunctional uterine bleeding market is segmented into pharmacologic treatment, hysterectomy, endometrial ablation, and others. The pharmacologic treatment includes oral contraceptives, estrogen, progestins, desmopressin and others.
On the basis of end user, the dysfunctional uterine bleeding market is segmented into hospitals, clinics, diagnostic centers, pharmaceutical companies, and others.
Research Methodology
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Regional Analysis of the Global Dysfunctional Uterine Bleeding Market  Â
America is the largest market for dysfunctional uterine bleeding market across the globe. The dysfunctional uterine bleeding market is driven by the rising prevalence of uterine cancer and other uterine disorders among women. According to the American Cancer Institute, about 61,380 new cases of uterine cancer is estimated to be diagnosed in 2017.
Europe is the second largest market owing to an increasing demand for diagnosis and treatment measures for uterine cancer, fibroids and other disorders, and increasing emphasis on women healthcare.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by the increasing prevalence of menstrual disorders, rising awareness about causes of such disorders and early diagnosis and treatment measures among women. The market is also driven by rising prevalence of sexually transmitted diseases among women in the developing nations.
The Middle East & Africa also show a steady rise in the market owing to increasing focus on women and child health, and need of primary care services in developing regions.
Intended Audience
- Drug Manufacturers
- Drug Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
